Tachykinin (nk1) Receptor Antagonists


The invention concerns tachykinin antagonists. The compounds are alcohols, amines and prodrugs of nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma, multiple sclerosis, rheumatoid arthritis, the management of pain, migraine, and antiemetic agents.

IPC Classifications
US Classifications
Download PDF
Document Preview
Document History
  • Publication: Mar 11, 1997
  • Application: Sep 7, 1995
    US US 52522895 A
  • Priority: Sep 7, 1995
    US US 52522895 A
  • Priority: Jun 6, 1994
    US US 25482194 A

Download Citation

Sign in to the Lens